Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study
| Autor: | Masashi Kameyama, Tomomichi Iizuka, Kazumasa Hayasaka, Hideo Ogata, Atsuyuki Kurashima, Yuka Sasaki, Kozo Morimoto, Hajime Goto |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Tau hyperphosphorylation medicine.medical_specialty Amyloid β Cognitive Neuroscience lcsh:Geriatrics Pharmacology lcsh:RC346-429 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Amyloid-β Original Research Article FDG-PET lcsh:Neurology. Diseases of the nervous system Rifampicin business.industry Follow up studies medicine.disease lcsh:RC952-954.6 Psychiatry and Mental health Preventive therapy 030104 developmental biology Oligomer Alzheimer disease Alzheimer's disease business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Dementia and Geriatric Cognitive Disorders EXTRA Dementia and Geriatric Cognitive Disorders Extra, Vol 7, Iss 2, Pp 204-214 (2017) |
| ISSN: | 1664-5464 |
| DOI: | 10.1159/000477343 |
| Popis: | Background: Rifampicin was reported to inhibit amyloid-β oligomerization and tau hyperphosphorylation in mouse models and could serve as a promising available medicine for the prevention of Alzheimer disease (AD). To examine whether rifampicin has such preventive effects in humans, we retrospectively reviewed 18F-FDG-PET findings of elderly patients with mycobacterium infection treated with rifampicin. Methods: Forty nondemented elderly patients treated with rifampicin for mycobacterium infections who showed AD-type hypometabolism were enrolled. The hypometabolic patterns were evaluated with stereotaxic statistical analysis and region of interest analysis. Results: Before treatment, AD-type hypometa bolism was observed in 12 patients. The FDG uptake in the posterior cingulate cortex (PCC) was improved or stabilized in 6 patients after 12-month therapy (450 mg/day), whereas another 6 patients with 6-month therapy showed a decreased FDG uptake in the PCC. In patients who underwent FDG-PET only after treatment, the metabolic decline in the PCC was significantly milder in patients with ≥12 months of rifampicin treatment than in those with 6 months of treatment. Multiple regression analysis revealed that the dose of rifampicin and treatment duration significantly influenced FDG uptake in the PCC. Conclusion: The preventive effect of rifampicin depended on the dose and the treatment duration, and the effect needs at least 450 mg daily for 1 year. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|